Definitive Contract 75N93021C00042
Award Date 9/3/21
Potential Completion Date 11/22/22
Potential Value $300K
Federal Agency
Awardee
Ultimate Awardee
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Austin, TX 78750, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
7
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Via Therapeutics, LLC has been awarded a firm fixed price definitive contract valued at $3,599,145 by the Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases. This contract is set aside for small businesses and will support Phase I of Via Therapeutics' SBIR program efforts to develop an inhaled delivery method for clofazimine, an important drug for treating tuberculosis. The contract aligns with the agency's solicitation...
- The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases (HHS-NIH-NIAID) awarded a $1.5M definitive contract to Via Therapeutics, LLC, doing business as Via Therapeutics LLC, located in Austin, Texas. The firm fixed price contract runs from September 15, 2023 through September 14, 2026 to support Via Therapeutics' Phase II award for small business innovation research related to developing new therapeutics. No subcontractors...
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, awarded a $220,582 Small Business Innovation Research (SBIR) Phase I contract to Oak Therapeutics Inc., a pharmaceutical company based in Westlake Village, California. The contract is for the development of oral dissolving strips for the delivery of isoniazid, a medication used to treat tuberculosis, in children and adults. This contract is a Firm Fixed Price definitive...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Small Business Innovation Research (SBIR) Program Phase I contract to Northbound Therapeutics, Inc., a minority-owned, woman-owned small business, to develop an inhaled clofazimine powder as a novel treatment for multidrug-resistant tuberculosis (MDR-TB). The contract, valued at $37,500, is for the formulation and preclinical evaluation of the inhaled clofazimine powder. This SBIR contract is a Firm Fixed Price...
- The U.S. Department of Health and Human Services (HHS) National Institute of Allergy and Infectious Diseases (NIAID) awarded a $224,946 Small Business Innovation Research (SBIR) Phase I contract to Aerophase, Inc., a self-certified small disadvantaged business, for the "Treatment of Tuberculosis with Inhaled Delivery of Clofazimine." The contract is a firm-fixed-price definitive contract with a completion date of July 31, 2016. This contract supports research and development of an...
- This federal contract award was made by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Creare LLC, doing business as Creare, a small business engineering research and development company. The $591,870.00 Small Business Innovation Research (SBIR) Phase I contract is for the development of an optimized dry powder formulation and delivery system for the anti-tuberculosis drug clofazimine. The...
- The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $599,582.00 firm fixed price contract to Virtici LLC, a for-profit limited liability company, to develop toll-like receptor agonists to strengthen sublingual vaccines. This contract is a small business set-aside. Virtici LLC is a biomedical research and development company that has received over $3 million in prior federal contracts and grants from agencies...
- This is a $599,471.00 Firm Fixed Price Definitive Contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to L2 Diagnostics LLC, a small business based in Woodbridge, Connecticut. The contract is for a Small Business Innovation Research (SBIR) Program Phase I project to develop a "Therapeutic Vaccine Platform to Boost Immune Responses in Tuberculosis". The contract has a total small business set-aside designation and a performance...
- Zymeron Corporation has been awarded a $300,000 firm fixed price definitive contract by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to deliver an orodispersible film formulation of a second line drug for pediatric tuberculosis treatment. The contract is set aside for total small businesses and will be completed by August 31, 2022. Performance will take place in Durham, North Carolina. This award supports the National Institute of Allergy and...
- The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a Small Business Innovation Research (SBIR) Phase I contract to Luna Innovations Incorporated, a leading provider of advanced fiber optic sensing and measurement systems. The contract, valued at $224,997, is for the development of "INNOVATIVE ORAL FORMULATIONS FOR ANTI-TB DRUGS." This Firm Fixed Price contract has an ultimate completion date of August 25, 2017. Luna Innovations, a for-profit manufacturer, is...